Psoriasis

Dermavant has submitted a New Drug Application (NDA) to the FDA seeking approval for its novel topical for the treatment of mild, moderate, and severe plaque psoriasis in adult patients.

Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.

AxisBiotix-Ps food supplement shows positive results in a recent consumer study evaluating its efficacy for psoriasis treatment.

Thanks to targeted drugs in early-stage development, patients with generalized pustular psoriasis (GPP) will one day likely have FDA-approved treatments for the disease, according to one expert.

In this episode, we take a look back at what happened at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), including exclusive interviews with two KOLs about their presentations regarding climate change and new data on biologics for psoriasis.

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.

A new study shows a possible association between fasting and skin improvement in psoriasis patients.

Psoriasis patients may have a higher risk of contracting COVID-19, according to study results recently presented at AAD VMX 2021.

Research presented at the EADV Spring Symposium 2021 investigated the link between gut bacteria and skin inflammation.

After data from a phase 3 study, FDA opens potential for apremilast to be the first and only approved oral therapy for mild to moderate plaque psoriasis.

Mark Lebwohl, MD, discusses his recent presentation from AAD VMX 2021 regarding new data for various biologics for the treatment of psoriasis.

Study findings show calcipotriene-betamethasone foam to be safe and moderately effective in skin of color patients with psoriasis but failed to meet several secondary endpoints and to demonstrate statistically significant changes.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

New data on the safety and efficacy of roflumilast foam (ARQ-154, Arcutis Biotherapeutics) for scalp and body psoriasis was presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.

A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.

A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.

Sun Pharmaceuticals announces the publication of results from its 5-year extension studies evaluating the safety, efficacy and tolerability of tildrakizumab-asmn.

Pre- and postmarketing psoriasis studies support novel drug results and new labeling.